Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ENTRECTINIB Cause Metastases to central nervous system? 42 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 42 reports of Metastases to central nervous system have been filed in association with ENTRECTINIB (Rozlytrek). This represents 2.8% of all adverse event reports for ENTRECTINIB.

42
Reports of Metastases to central nervous system with ENTRECTINIB
2.8%
of all ENTRECTINIB reports
5
Deaths
1
Hospitalizations

How Dangerous Is Metastases to central nervous system From ENTRECTINIB?

Of the 42 reports, 5 (11.9%) resulted in death, 1 (2.4%) required hospitalization, and 1 (2.4%) were considered life-threatening.

Is Metastases to central nervous system Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ENTRECTINIB. However, 42 reports have been filed with the FAERS database.

What Other Side Effects Does ENTRECTINIB Cause?

Dizziness (143) Off label use (137) Death (126) Disease progression (105) Taste disorder (68) No adverse event (65) Constipation (60) Fatigue (60) Drug ineffective (58) Blood creatinine increased (57)

What Other Drugs Cause Metastases to central nervous system?

TRASTUZUMAB (1,180) CAPECITABINE (663) OSIMERTINIB (560) PERTUZUMAB (540) PACLITAXEL (498) NIVOLUMAB (495) DABRAFENIB (451) CARBOPLATIN (413) DOCETAXEL (410) ADO-TRASTUZUMAB EMTANSINE (386)

Which ENTRECTINIB Alternatives Have Lower Metastases to central nervous system Risk?

ENTRECTINIB vs ENZALUTAMIDE ENTRECTINIB vs EPCORITAMAB ENTRECTINIB vs EPCORITAMAB-BYSP ENTRECTINIB vs EPERISONE ENTRECTINIB vs EPHEDRINE

Related Pages

ENTRECTINIB Full Profile All Metastases to central nervous system Reports All Drugs Causing Metastases to central nervous system ENTRECTINIB Demographics